Galectin Therapeutics Names Industry-Veteran Jack W. Callicutt Chief Financial Officer

Galectin Therapeutics Names Industry-Veteran Jack W. Callicutt Chief Financial
                                   Officer

PR Newswire

NORCROSS, Ga., June 21, 2013

NORCROSS, Ga., June 21, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ:
GALT), the leading developer of therapeutics that target galectin proteins to
treat fibrosis and cancer, today announced the appointment of Jack W.
Callicutt to the position of Chief Financial Officer, effective July 1, 2013.

Mr. Callicutt will lead the Company's financial activities, including
financial reporting, accounting, risk management, public company governance,
interaction with capital markets, and public and investor relations. As a
member of the senior management team, Mr. Callicutt will play a key role in
shaping corporate strategy as we advance key product assets in the clinic. He
will also help assure that the company has the financial resources to realize
its vision for its pipeline of clinical development assets which is critical
to create shareholder value.

"Jack's demonstrated leadership and deal-making capabilities coupled with his
financial management experience and industry knowledge makes him an ideal fit
with the needs of the company and further consolidates our leadership group in
the Atlanta office. I am looking forward to working closely with Jack and am
excited to add an individual of Jack's caliber to our management team," said
Dr. Peter G. Traber, Chief Executive Officer and Chief Medical Officer of
Galectin Therapeutics Inc. "I also wish to sincerely thank Mr. Thomas McGauley
for his years of service to the company, including the last 14 months as
acting CFO, and for agreeing to work closely with Jack to assure an orderly
transition."

Mr. Callicutt has over 22 years of public and private company experience
including more than a decade of audit, tax, and SEC registrant experience with
a major accounting firm. He was most recently CFO for REACH Health, Inc., a
telemedicine firm, where he completed a $4 MM private placement. Previous
positions include CFO of Vystar Corporation, a public medical device company
whose latex products are devoid of antigenic proteins, where he led all areas
of financial reporting, accounting, treasury, risk management and
administration and secured over $4.5 MM in financing. Previous experiences
also include CFO roles at private companies including IVOX and Tikvah
Therapeutics, and at Coratus Genetics, a publicly traded biopharmaceutical
company. His broad background of experiences spanning a variety of technology
intensive industries underpinned by a decade-long senior level role at
Deloitte, positions him well to meaningfully contribute to the advancement of
the company.

Jack is a Certified Public Account and graduated cum laude with a BBA degree
in Accounting and Computer science from Delta State University. Jack is active
in community affairs such as the Atlanta Community Food Bank, Habitat for
Humanity, and resides with his family in Alpharetta, Georgia.

About Galectin Therapeutics
Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for the treatment of fibrotic liver disease and
cancer based on the Company's unique understanding of galectin proteins, key
mediators of biologic function. We are leveraging extensive scientific and
development expertise as well as established relationships with external
sources to achieve cost effective and efficient development. We are pursuing a
clear development pathway to clinical enhancement and commercialization for
our lead compounds in liver fibrosis and cancer. Additional information is
available at www.galectintherapeutics.com. Follow us on Twitter @GalectinGALT

SOURCE Galectin Therapeutics

Website: http://www.galectintherapeutics.com
 
Press spacebar to pause and continue. Press esc to stop.